ZYME Stock Analysis: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$21.81
-0.13 (-0.59%)
▼
5d:
-5.17%
30d:
-17.1%
90d:
-18.04%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ZYME shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ZYME shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.88
Based on -14.6% avg growth
INTRINSIC VALUE TODAY
$5.51
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $21.81, which is considered oversold relative to its 30-day fair value range of $22.77 to $25.80. From a valuation perspective, the stock is trading at a discount (Forward PE: 26.3) compared to its historical average (61.8). Remarkably, the market is currently pricing in an annual earnings decline of 24.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is in a downtrend. The price is currently testing key support at $21.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+80.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ZYME is in a downtrend. The price is currently testing key support at $21.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+80.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$22.77 -
$25.80
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
Protect Your Profits
Holding ZYME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 80.3% below Wall St target ($39.33)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$22.77 -
$25.80
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.27
(10.4%)
Support & Resistance Levels
Support Level
$21.52
Resistance Level
$24.25
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.34
Wall Street Target
$39.33
(+80.3%)
Revenue Growth (YoY)
-91.1%
Profit Margin
-126.3%
Valuation Discount vs History
-24.7% cheaper
PE vs Historical
26.3 vs 61.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.7%
(market-implied from PE analysis)
1-Year Target
$19.63
(-10%)
2-Year Target
$17.67
(-19%)
3-Year Target
$15.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 26→62)
$37.30
(+71%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.3, Growth: -33.1%)
$15.90
(+-27%)
Base:
(SPY PE: 20.7, Growth: -33.1%)
$12.51
(-43%)
Bear:
(PE: 17.6, Growth: -33.1%)
$10.64
(-51%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.3 to 61.8
Stabilization Target:
$51.17
(+134.6%)
PE Expansion Potential:
+134.6%
Share & Embed Analysis
Last updated: August 03, 2026 8:25 PM ET
Data refreshes hourly during market hours. Next update: 9:25 PM
Data refreshes hourly during market hours. Next update: 9:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
